Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. The company has two clinical development programs and one drug discovery program underway. Its clinical development programs include CO-1686, which is Phase I/II study is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is the subject of a development program for the treatment of non-small cell lung cancer in patients with activating EGFR mutations, as well as the primary resistance mutation, T790M; and rucaparib, an oral inhibitor of poly (ADP-ribose) polymerase that is being explored in Phase I/II clinical trials for ovarian and breast cancer patients with BRCA mutations and other DNA repair deficiencies. The company's drug discovery program includes its mutant cKit inhibitor discovery program targeting the resistance mutations that occur in the majority of gastrointestinal stromal tumor patients and result in disease progression. It has license agreements with Avila Therapeutics, Inc. and Pfizer Inc.; a drug discovery collaboration agreement with Array BioPharma Inc.; and collaborations with Roche Molecular Systems and Foundation Medicine, Inc. Clovis Oncology, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
Biopharmaceutical Disease Chemical Compounds Organic Compounds Drug Discovery Breast Cancer Non Small Cell Lung Cancer Lung Cancer Epidermal Growth Factor Receptor Lactams Treatment Of Non Small Cell Lung Cancer Indoles Gastrointestinal Stromal Tumor Heterocyclic Compounds